Healrna announced that it has received $29 million in a pre series A round of funding led by new investor, Ming Bioventures on March 10, 2023. The transaction also included participation from China-Singapore Suzhou Industrial Park Development Group Co., Ltd., Sequoia China Investment Management LLP, Shunwei, Inc., AAMA Angel Fund I, a fund managed by Asia America MultiTechnology Association, Investment Arm.
China-Singapore Suzhou Industrial Park Development Group Co., Ltd.
Equities
601512
CNE100003Y65
Real Estate Development & Operations
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.31 CNY | -3.03% | +1.09% | +7.78% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.78% | 1.72B | |
+34.25% | 28.37B | |
+6.96% | 26.59B | |
-11.96% | 27.34B | |
+15.36% | 25.28B | |
+48.22% | 23.37B | |
+6.98% | 20.39B | |
+1.89% | 19.71B | |
+28.49% | 16.22B | |
-13.52% | 15.11B |
- Stock Market
- Equities
- 601512 Stock
- News China-Singapore Suzhou Industrial Park Development Group Co., Ltd.
- Healrna announced that it has received $29 million in funding from China-Singapore Suzhou Industrial Park Development Group Co., Ltd., Sequoia China Investment Management LLP, Shunwei, Inc., Ming Bioventures, Asia America MultiTechnology Association, Investment Arm